Very well done article in the Business section of the NY Times was published today. Interviewed is Dr. Diane Sylvestre from the OASIS clinic in Oakland, whose patient population consists mainly of current or recovered IV drug users. I was at the presentation at Vertex she mentions and she makes a very valid point that the drug companies developing antiviral therapies for HCV have largely ignored 'the real face of HCV'. The industry counterpoint is that patients like Dr. Sylvestre's are challenged from a compliance standpoint, therefore not the ideal patient population to do clinical studies in. A happy medium must be made between industry and treaters like Dr. Sylvestre.
Read the full article here: http://www.nytimes.com/2010/07/22/business/22hepatitis.html?scp=1&sq=%2b%22Centers+for+Disease+Control%22&st=nyt
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment